Claims for Patent: 10,835,515

Summary for Patent: 10,835,515

Title:	Carboxamide derivative and its diastereomers in stable crystalline form
Abstract:	The present disclosure relates to solid crystalline forms of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-- hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament. ##STR00001##
Inventor(s):	Tormakangas; Olli (Turku, FI), Heikkinen; Terhi (Lieto, FI)
Assignee:	ORION CORPORATION (Espoo, FI)
Application Number:	16/458,435
Patent Claims:	1. A pharmaceutical dosage form in the form of a tablet or a capsule for oral administration comprising crystalline form I of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having an X-ray powder diffraction pattern comprising characteristic peaks at about 8.5, 10.4, 16.6, 16.9, and 24.3 degrees 2-theta, together with a pharmaceutical excipient. 2. The pharmaceutical dosage form according to claim 1, wherein the crystalline form I of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) further has an X-ray powder diffraction pattern comprising characteristic peaks at about 9.7, 15.9, 19.2, 21.8, and 25.5 degrees 2-theta. 3. A method for the treatment of prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical dosage form according to claim 1 or 2.